Pentoxifylline in children with acute encephalitis syndrome: a randomized control trial

Area of Science:

• Pediatric Neurology
• Infectious Diseases
• Clinical Pharmacology

Background:

• Acute encephalitis syndrome (AES) carries high mortality and neurological sequelae risks, driven by inflammatory responses.
• Current treatments lack proven immunomodulatory adjuncts for pediatric AES.
• Pentoxifylline modulates inflammation and was investigated for potential benefits in AES.

Purpose of the Study:

• To assess the efficacy of pentoxifylline in improving Glasgow Coma Scale (GCS) in children with AES.
• To evaluate adverse effects and sequelae frequency associated with pentoxifylline use in pediatric AES patients.

Main Methods:

• An open-label randomized controlled trial (RCT) involving 44 children (1 month to 14 years) diagnosed with AES.
• Participants received either standard treatment plus pentoxifylline or standard treatment alone.
• Primary outcome was time to a 3-point GCS improvement or normalization; secondary outcomes included adverse events and sequelae.

Main Results:

• No significant difference was observed in the time to GCS improvement between the pentoxifylline group (26 hours) and the control group (28 hours) (p=0.92).
• Mechanical ventilation requirements, mortality rates, and sequelae frequencies did not differ significantly between groups.
• Adverse event rates were comparable between the pentoxifylline and control groups, indicating good tolerability.

Conclusions:

• Adjunctive pentoxifylline did not demonstrate significant clinical benefits for children with AES.
• Pentoxifylline was found to be safe and well-tolerated in this pediatric AES cohort.
• Larger, multicenter trials stratified by etiology and incorporating biomarkers are recommended to identify potential benefits in specific subgroups of AES patients.